CTLA4 and neoplasm: It soon became evident that CTLA-4 blockade as monotherapy was effective when tumors were intrinsically immunogenic, there was a lower tumor burden, and infiltrating T cells were present but not in a tolerant/exhausted status, which are all limitations suggesting to combine CTLA-4 blockade with other therapies.